CXCR4-independent rescue of the myeloproliferative defect of the Gata1 low myelofibrosis mouse model by aplidin®

Journal of Cellular Physiology

Volumn 225, Issue 2, 2010, Pages 490-499

  Verrucci, Maria ^a   Pancrazzi, Alessandro ^b   Aracil, Miguel ^c   Martelli, Fabrizio ^a   Guglielmelli, Paola ^b   Zingariello, Maria ^d   Ghinassi, Barbara ^d,e   D'Amore, Emanuela ^a   Jimeno, José ^c,f   Vannucchi, Alessandro M ^b   Migliaccio, Anna Rita ^a,e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c PHARMAMAR S A   (Spain)

^d UNIVERSITY OF CHIETI   (Italy)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f USP Dexeus   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLODEPSIPEPTIDE; DEHYDRODIDEMNIN B; PROTEIN P27; TRANSCRIPTION FACTOR GATA 1; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CDKN1B PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEPSIPEPTIDE; GATA1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE MARROW; CANCER CELL; CELL DENSITY; CELL MATURATION; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG SAFETY; EXTRAMEDULLARY HEMATOPOIESIS; HEMATOPOIETIC CELL; IN VITRO STUDY; MALE; MEGAKARYOCYTE; MICROENVIRONMENT; MICROVASCULATURE; MOUSE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NONHUMAN; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; AGE DISTRIBUTION; ANIMAL; BONE MARROW CELL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; WEIGHT REDUCTION;

MUS;

AGE DISTRIBUTION; ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; MALE; MICE; MUTATION; PRIMARY MYELOFIBROSIS; RECEPTORS, CXCR4; STEM CELLS; WEIGHT LOSS;

EID: 77956509712     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22228     Document Type: Article

References (49)

1. Albella B, Faircloth G, Lopez-Lazaro L, Guzman C, Jimeno J, Bueren JA. 2002. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. Comparison with the clinical results. Eur J Cancer 38:1395-1404.
2. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A. 2005. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51-63. (Pubitemid 40126382)
3. Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. 2005. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol 16:1667-1674. (Pubitemid 41510142)
4. Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, Le Bousse-Kerdiles MC, Barosi G, Vannucchi AM. 2008. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 26:1920-1930.
5. Bravo SB, Garcia-Rendueles ME, Seoane R, Dosil V, Cameselle-Teijeiro J, Lopez-Lazaro L, Zalvide J, Barreiro F, Pombo CM, Alvarez CV. 2005. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clin Cancer Res 11:7664-7673. (Pubitemid 41611608)
6. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M. 2003. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR- 1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17:52-59. (Pubitemid 36175888)
7. Broxmeyer HE. 2008. Chemokines in hematopoiesis. Curr Opin Hematol 15:49-58.
8. Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K. 2008. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer 98:1966-1974. (Pubitemid 351821559)
9. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. 2005. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med 11:886-891. (Pubitemid 41161122)
10. Cervantes F, Mesa R, Barosi G. 2007. New and old treatment modalities in primary myelofibrosis. Cancer J 13:377-383.
11. Cheng T, Rodrigues N, Dombkowski D, Stier S, Scadden DT. 2000. Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med 6:1235-1240.
12. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR. 1998. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 78:739-744.
13. Ferme C, Mateos MV, Szyldergemajn S, Zucca E, Espinoza J, Briones J, Morschhauser F, Gisselbrecht C, Ribrag V. 2008. Plitidepsin is active in peripheral T-cell lynphoma (PTCL):A subset analysis from an ongoing multicenter phase II trial. Blood 112:1566.
14. Fukuchi Y, Yamato K, Kawamura C, Ikeda Y, Kizaki M. 2006. p27KIP1 and GATA-1 are potential downstream molecules in activin A-induced differentiation and apoptosis pathways in CML cells. Oncol Rep 16:1099-1103.
15. Garimella R, Kacena MA, Tague SE, Wang J, Horowitz MC, Anderson HC. 2007. Expression of bone morphogenetic proteins and their receptors in the bone marrowmegakaryocytes of GATA-1(low) mice: A possible role in osteosclerosis. J Histochem Cytochem 55:745-752. (Pubitemid 46981771)
16. Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi AM, Migliaccio G, Orkin SH, Migliaccio AR. 2007. The hypomorphic Gata1low mutation alters the proliferation/ differentiation potential of the common megakaryocytic-erythroid progenitor. Blood 109:1460-1471. (Pubitemid 46239577)
17. Ghinassi B, Martelli F, Verrucci M, D'Amore E, Migliaccio G, Vannucchi AM, Hoffman R, Migliaccio AR. 2010. Evidence for organ-specific stem cell microenvironments. J Cell Physiol 223:460-470.
18. Gomez SG, Bueren JA, Faircloth GT, Jimeno J, Albella B. 2003. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 31:1104-1111.
19. Gonzalez-Santiago L, Suarez Y, Zarich N, Munoz-Alonso MJ, Cuadrado A, Martinez T, Goya L, Iradi A, Saez-Tormo G, Maier JV, Moorthy A, Cato AC, Rojas JM, Munoz A. 2006. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 13:1968-1981. (Pubitemid 44542409)
20. Gu Y, Filippi MD, Cancelas JA, Siefring JE, Williams EP, Jasti AC, Harris CE, Lee AW, Prabhakar R, Atkinson SJ, Kwiatkowski DJ, Williams DA. 2003. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 302:445-449. (Pubitemid 37296270)
21. Huang Z, Dore LC, Li Z, Orkin SH, Feng G, Lin S, Crispino JD. 2009. GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol. 29:5168-5180.
22. Kacena MA, Shivdasani RA, Wilson K, Xi Y, Troiano N, Nazarian A, Gundberg CM, Bouxsein ML, Lorenzo JA, Horowitz MC. 2004. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res 19:652-660. (Pubitemid 41071226)
23. Lane SW, Scadden DT, Gilliland DG. 2009. The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood 114:1150-1157.
24. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyre MC, Le Bousse- Kerdiles MC. 2008. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112:3026-3035.
25. Martelli F, Ghinassi B, Panetta B, Alfani E, Gatta V, Pancrazzi A, Bogani C, Vannucchi AM, Paoletti F, Migliaccio G, Migliaccio AR. 2005. Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. Blood 106:4102-4113. (Pubitemid 41775915)
26. Mateos MV, Cibeira MT, Richardson P, Blade J, Prosper F, Oriol A, Rubia J, Alegre A, Lahuerta JJ, Garcia-Sanz R, Mitsiades CS. 2008. Final results of a phase II trial with plitidepsin (Aplidin) alone and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 112:3700.
27. Messina G, Blasi C, La Rocca SA, Pompili M, Calconi A, Grossi M. 2005. p27Kip1 acts downstream of N-cadherin-mediated cell adhesion to promote myogenesis beyond cell cycle regulation. Mol Biol Cell 16:1469-1480. (Pubitemid 40349580)
28. Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, Xu M, Jiang Y, Nakamoto B, Papayannopoulou T, Hoffman R. 2008. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol 36:158-171.
29. Migliaccio AR, Martelli F, Verrucci M, Sanchez M, Valeri M, Migliaccio G, Vannucchi AM, Zingariello M, Di Baldassarre A, Ghinassi B, Rana RA, van Hensbergen Y, Fibbe WE. 2009. GATA1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic GATA1low mutation. Blood 114:2107-2120.
30. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC. 2008. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 68:5216-5225.
31. Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A. 2007. Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther 6:1310-1316. (Pubitemid 46711994)
32. Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N, Martinez T, Alvarez E, Rojas JM, Munoz A. 2008. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. J Pharmacol Exp Ther 324:1093-1101. (Pubitemid 351397837)
33. Munoz-Alonso MJ, Gonzalez-Santiago L, Martinez T, Losada A, Galmarini CM, Munoz A. 2009. The mechanism of action of plitidepsin. Curr Opin Investig Drugs 10:536-542.
34. Orkin SH, Zon LI. 2008. Hematopoiesis: An evolving paradigm for stem cell biology. Cell 132:631-644. (Pubitemid 351260057)
35. Pardanani A. 2008. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 22:23-30.
36. Ray A, James MK, Larochelle S, Fisher RP, Blain SW. 2009. p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol Cell Biol 29:986-999.
37. Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, Bruno E, Lindgren V, Xu M, Hoffman R. 2007. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 67:6417-6424. (Pubitemid 47037526)
38. Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL. 2006. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 57:7-14. (Pubitemid 41704919)
39. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, Broggini M, D'Incalci M, Ribatti D, Giavazzi R. 2004. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 90:2418-2424. (Pubitemid 38961909)
40. Tefferi A. 2000. Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265.
41. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. 2007. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097.
42. Teicher B, Andrews P. 2004. In vivo methods. In: Teicher BA, editor. Anticancer drug development guide, 2nd edition. Totama, NJ: Humana Press. p 110.
43. Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, Zingariello M, Di Baldassarre A, Rana RA, Lorenzini R, Alfani E, Migliaccio G, Migliaccio AR. 2005a. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 105:3493-3501. (Pubitemid 40628191)
44. Vannucchi AM, Pancrazzi A, Guglielmelli P, Di Lollo S, BoganiC, Baroni G, Bianchi L, Migliaccio AR, Bosi A, Paoletti F. 2005b. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol 167:849-858. (Pubitemid 41216367)
45. Varricchio L, Mancini A, Migliaccio AR. 2009. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol 2:315-334.
46. Walmsley MJ, Ooi SK, Reynolds LF, Smith SH, Ruf S, Mathiot A, Vanes L, Williams DA, Cancro MP, Tybulewicz VL. 2003. Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science 302:459-462.
47. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. 2008. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell 133:340-353.
48. Zhan H, Spivak JL. 2009. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol 7:334-342.
49. Zon LI, Tsai SF, Burgess S, Matsudaira P, Bruns GA, Orkin SH. 1990. The major human erythroid DNA-binding protein (GF-1): Primary sequence and localization of the gene to the X chromosome. Proc Natl Acad Sci USA 87:668-672.